Prashant Nambiar

Prashant Nambiar is Senior Vice President of R&D at Strand Therapeutics where he is leading Discovery, Nonclinical, Translational, and Data Science. Prior to Strand, Prashant was Vice President at 2seventybio and bluebird bio leading the preclinical and translational group developing cell and gene therapies for oncology and rare disease indications. Prashant started his career in academia at MIT followed by 18+ years in biotech and pharma including Genzyme, Pfizer, bluebird bio and 2seventybio. He has worked on various modalities such as small molecules, biologics, AAV, cell and gene editing therapies at various stages of development including discovery, target selection, preclinical development, and beyond. His expertise is in Translational Biology, Pathology, and Toxicology with a focus on bringing transformative therapies from bench to the clinic and beyond. He is passionate about leveraging data in drug R&D and had built a data operations team at Pfizer to execute on that strategy. Prashant’s PhD is in cancer biology, specifically understanding the molecular pathogenesis of precancerous lesions in the colon. He has board certifications in Toxicology and Veterinary Pathology. He also has an MBA from Sloan School of Business, MIT.